Levofloxacin
- Generic Name
- Levofloxacin
- Brand Names
- Levaquin, Quinsair
- Drug Type
- Small Molecule
- Chemical Formula
- C18H20FN3O4
- CAS Number
- 100986-85-4
- Unique Ingredient Identifier
- RIX4E89Y14
- Background
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...
- Indication
In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...
- Associated Conditions
- Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria
- Associated Therapies
- -
A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 1109
- Registration Number
- NCT00210886
Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- City, University of London
- Target Recruit Count
- 35000
- Registration Number
- NCT00136344
- Locations
- 🇧🇪
University Hospital Antwerp, UZA Ophthalmology, Antwerp, Belgium
🇮🇹Ospedale Borgo Trento, Verona, Italy
🇧🇪Jan Yperman Ziekenhuis, Ieper, Belgium
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
- Conditions
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 434
- Registration Number
- NCT00081575
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00020865
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Cancer Research Campaign Clinical Trials Centre
- Registration Number
- NCT00005590
- Locations
- 🇬🇧
University of Birmingham, Birmingham, England, United Kingdom
A Study of the Effectiness and Safety of Levofloxacin in Treating Children With a Rapid and Severe Onset of Infection and Inflammation of the Middle Ear That is Difficult to Treat
- Conditions
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 206
- Registration Number
- NCT00044473
A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 691
- Registration Number
- NCT00034736
The Treatment of Tuberculosis in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 650
- Registration Number
- NCT00001033
- Locations
- 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- R W Johnson Pharmaceutical Research Institute
- Registration Number
- NCT00002249
- Locations
- 🇺🇸
R W Johnson Pharmaceutical Research Institute, Raritan, New Jersey, United States
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 525
- Registration Number
- NCT00000796
- Locations
- 🇺🇸
Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Bronx Lebanon Hosp Ctr, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.